RESUMEN
OBJECTIVE: There is considerable interest in using bumetanide, a chloride importer Na-K-Cl cotransporter antagonist, for treatment of neurological diseases, such as epilepsy or ischemic and traumatic brain injury, that may involve deranged cellular chloride homeostasis. However, bumetanide is heavily bound to plasma proteins (~98%) and highly ionized at physiological pH, so that it only poorly penetrates into the brain, and chronic treatment with bumetanide is compromised by its potent diuretic effect. METHODS: To overcome these problems, we designed lipophilic and uncharged prodrugs of bumetanide that should penetrate the blood-brain barrier more easily than the parent drug and are converted into bumetanide in the brain. The feasibility of this strategy was evaluated in mice and rats. RESULTS: Analysis of bumetanide levels in plasma and brain showed that administration of 2 ester prodrugs of bumetanide, the pivaloyloxymethyl (BUM1) and N,N-dimethylaminoethylester (BUM5), resulted in significantly higher brain levels of bumetanide than administration of the parent drug. BUM5, but not BUM1, was less diuretic than bumetanide, so that BUM5 was further evaluated in chronic models of epilepsy in mice and rats. In the pilocarpine model in mice, BUM5, but not bumetanide, counteracted the alteration in seizure threshold during the latent period. In the kindling model in rats, BUM5 was more efficacious than bumetanide in potentiating the anticonvulsant effect of phenobarbital. INTERPRETATION: Our data demonstrate that the goal of designing bumetanide prodrugs that specifically target the brain is feasible and that such drugs may resolve the problems associated with using bumetanide for treatment of neurological disorders.
Asunto(s)
Encéfalo/efectos de los fármacos , Bumetanida/uso terapéutico , Epilepsia/tratamiento farmacológico , Suero/efectos de los fármacos , Inhibidores del Simportador de Cloruro Sódico y Cloruro Potásico/uso terapéutico , Potenciales de Acción/efectos de los fármacos , Animales , Animales Recién Nacidos , Encéfalo/citología , Encéfalo/metabolismo , Bumetanida/química , Bumetanida/farmacología , Convulsivantes/toxicidad , Modelos Animales de Enfermedad , Diuréticos/farmacología , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Epilepsia/inducido químicamente , Humanos , Técnicas In Vitro , Ratones , Neuronas/efectos de los fármacos , Pentilenotetrazol/toxicidad , Fenobarbital/uso terapéutico , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Inhibidores del Simportador de Cloruro Sódico y Cloruro Potásico/química , Inhibidores del Simportador de Cloruro Sódico y Cloruro Potásico/farmacología , Especificidad de la Especie , Factores de TiempoRESUMEN
In this contribution, a chemical collection of aromatic compounds was screened for inhibition on butyrylcholinesterase (BChE)'s hydrolase activity using Ellman's reaction. A set of diarylimidazoles was identified as highly selective inhibitors of BChE hydrolase activity and amyloid ß (Aß) fibril formation. New derivatives were synthesized resulting in several additional hits, from which the most active was 6c, 4-(3-ethylthiophenyl)-2-(3-thienyl)-1H-imidazole, an uncompetitive inhibitor of BChE hydrolase activity (IC50 BChE=0.10 µM; K(i)=0.073 ± 0.011 µM) acting also on Aß fibril formation (IC50=5.8 µM). With the aid of structure-activity relationship (SAR) studies, chemical motifs influencing the BChE inhibitory activity of these imidazoles were proposed. These bifunctional inhibitors represent good tools in basic studies of BChE and/or promising lead molecules for AD therapy.